Global Clinical Registry (GCR, 1452)

Trials

Studies that name Global Clinical Registry (GCR, 1452) as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:58 UTC. Showing 200 of 818. Open this list on ClinicalTrials.gov

• Ph3
  NCT03191396 · Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT03175120 · A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT03172494 · A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT03015207 · First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• N/A
  NCT02967757 · In-market Utilisation of Liraglutide Used for Weight Management in Europe

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph1
  NCT02964104 · A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02962440 · A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects

  Novo Nordisk A/S · completed · Healthy · study director
• Ph1
  NCT02958085 · Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph1
  NCT02933853 · A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02911948 · A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02906917 · A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02906930 · Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02863328 · Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02863419 · Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02845219 · A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02844790 · A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

  Novo Nordisk A/S · completed · Healthy · study director
• Ph1
  NCT02835235 · A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph3
  NCT02825251 · Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• N/A
  NCT02821052 · Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

  Novo Nordisk A/S · completed · Diabetes · study director
• N/A
  NCT02779413 · A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea

  Novo Nordisk A/S · completed · Diabetes · study director
• Ph3
  NCT02773368 · A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT02773355 · Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

  Novo Nordisk A/S · completed · Obesity · study director
• Ph1
  NCT02773381 · A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02762578 · Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT02754817 · A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02717858 · A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph3
  NCT02692716 · A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02670915 · Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• N/A
  NCT02662114 · Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02648217 · Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02648204 · Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02627287 · A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph4
  NCT02617693 · Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph2
  NCT02616562 · Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

  Novo Nordisk A/S · completed · Growth Hormone Disorder, Growth Hormone Deficiency in Children · study director
• Ph1
  NCT02612844 · A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• N/A
  NCT02608853 · Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02594033 · A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles

  Novo Nordisk A/S · completed · Diabetes · study director
• N/A
  NCT02580032 · Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

  Novo Nordisk A/S · completed · Growth Disorder, Growth Hormone Deficiency in Children · study director
• N/A
  NCT02568202 · Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

  Novo Nordisk A/S · completed · Haemostasis, Congenital Bleeding Disorder, Haemophilia B · study director
• Ph1
  NCT02568280 · Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT02568306 · A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph1
  NCT02557620 · Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph2
  NCT02541942 · Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors · study director
• Ph1
  NCT02536859 · Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT02501161 · A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2
• Ph1
  NCT02490787 · Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A · study director
• Ph1
  NCT02479022 · A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Healthy · study director
• Ph2
  NCT02470039 · Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph2
  NCT02461589 · Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph4
  NCT02453685 · A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph2
  NCT02453711 · Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph2
  NCT02443155 · A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT02420262 · A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02382939 · A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

  Novo Nordisk A/S · completed · Adult Growth Hormone Deficiency, Growth Hormone Disorder · study director
• N/A
  NCT02382757 · Changing Diabetes in Children

  Novo Nordisk A/S · terminated · Diabetes, Diabetes Mellitus, Type 1 · study director
• N/A
  NCT02321878 · Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT02306681 · A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02305381 · Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02304627 · Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT02300844 · Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph3
  NCT02298192 · A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT02255266 · Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02254291 · A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2
• Ph1
  NCT02249910 · Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT02249871 · Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT02243098 · Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• N/A
  NCT02241694 · To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A, Haemophilia B · study director
• Ph1
  NCT02239146 · Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

  Novo Nordisk A/S · completed · Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass · study director
• Ph1
  NCT02235961 · Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph1
  NCT02231684 · Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• N/A
  NCT02230618 · Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT02230631 · A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02220296 · A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

  Novo Nordisk A/S · completed · Healthy, Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT02212067 · A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02210871 · Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Hepatic Impaired
• Ph1
  NCT02207348 · Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• N/A
  NCT02207218 · To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A
• Ph3
  NCT02207374 · A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph2
  NCT02205528 · A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus Type 2 · study director
• Ph1
  NCT02172313 · Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT02162407 · A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT02161588 · A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Healthy · study director
• Ph1
  NCT02151409 · Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

  Novo Nordisk A/S · completed · Inflammation, Systemic Lupus Erythematosus, Rheumatoid Arthritis · study director
• Ph1
  NCT02148861 · A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Type 2 Diabetes Mellitus · study director
• Ph1
  NCT02147431 · A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02146079 · A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Healthy · study director
• Ph3
  NCT02141074 · Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia B · study director
• Ph3
  NCT02137850 · Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A · study director
• Ph3
  NCT02131272 · A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

  Novo Nordisk A/S · terminated · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02131246 · A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT02128932 · Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT02117622 · A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02100475 · A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT02098395 · The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph2
  NCT02097264 · A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

  Novo Nordisk A/S · withdrawn · Inflammation, Rheumatoid Arthritis · study director
• Ph1
  NCT02094521 · Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT02089451 · A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT02084810 · Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects

  Novo Nordisk A/S · withdrawn · Congenital Bleeding Disorder, Haemophilia A, Haemophilia A With Inhibitors · study director
• Ph1
  NCT02079870 · Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

  Novo Nordisk A/S · completed · Diabetes, Metabolism and Nutrition Disorder, Obesity · study director
• N/A
  NCT02077946 · A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02070510 · A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• N/A
  NCT02066766 · A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02064348 · A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT02060266 · Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph3
  NCT02054897 · Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02035371 · A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• N/A
  NCT02035384 · Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A · study director
• Ph3
  NCT02034513 · A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT02033239 · A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT02030600 · A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT02022254 · Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Healthy · study director
• Ph1
  NCT02016911 · Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Healthy · study director
• Ph1
  NCT02014259 · Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Healthy · study director
• Ph4
  NCT02008682 · The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT02005198 · Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

  Novo Nordisk A/S · completed · Growth Hormone Disorder, Adult Growth Hormone Deficiency · study director
• Ph1
  NCT02003677 · A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT01999322 · A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT01992588 · A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• N/A
  NCT01988532 · Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A, Haemophilia A With Inhibitors · study director
• N/A
  NCT01984372 · Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

  Novo Nordisk A/S · completed · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01978613 · Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT01973244 · A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

  Novo Nordisk A/S · completed · Growth Hormone Disorder, Growth Hormone Deficiency in Children · study director
• Ph4
  NCT01973231 · Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01967589 · Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph3
  NCT01959529 · A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01959555 · Project to Update the Study of Congenital Haemophilia in Spain

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A, Haemophilia B · study director
• N/A
  NCT01957592 · A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka

  Novo Nordisk A/S · withdrawn · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01955603 · A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

  Novo Nordisk A/S · completed · Inflammation, Rheumatoid Arthritis · study director
• Ph3
  NCT01952145 · A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01950650 · GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01949792 · A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A, Haemophilia A With Inhibitors · study director
• N/A
  NCT01950637 · GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01943084 · A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects

  Novo Nordisk A/S · completed · Growth Disorder, Healthy · study director
• Ph1
  NCT01934712 · A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• N/A
  NCT01934673 · A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01934686 · A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01931137 · A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph3
  NCT01930188 · Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01927861 · Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

  Novo Nordisk A/S · completed · Genetic Disorder, Noonan Syndrome · study director
• Ph1
  NCT01924637 · A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph2
  NCT01923181 · Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph4
  NCT01917656 · Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01916174 · A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Healthy · study director
• Ph4
  NCT01907854 · Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01900834 · Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01892319 · An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry

  Novo Nordisk A/S · completed · Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph4
  NCT01892020 · Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01890993 · Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01885208 · Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01880736 · A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01876745 · A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Glanzmann's Disease · study director
• N/A
  NCT01877200 · A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01868568 · Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT01868555 · Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT01868529 · Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT01868581 · Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph4
  NCT01868542 · A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01866748 · Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2, Healthy · study director
• Ph1
  NCT01865305 · Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01865292 · Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01865331 · Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph1
  NCT01865318 · Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT01865279 · Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01862367 · Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Congenital FXIII Deficiency · study director
• Ph3
  NCT01850615 · Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01849289 · A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01848002 · Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Congenital FXIII Deficiency, Healthy · study director
• Ph1
  NCT01847989 · Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Congenital FXIII Deficiency, Healthy · study director
• N/A
  NCT01846312 · An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT01836523 · The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT01835431 · A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph3
  NCT01831765 · Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• N/A
  NCT01830712 · A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors · study director
• N/A
  NCT01821846 · Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01819129 · Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01814137 · A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01809184 · A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01796366 · A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01789593 · A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT01789086 · A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years

  Novo Nordisk A/S · completed · Metabolism and Nutrition Disorder, Obesity · study director
• Ph1
  NCT01780272 · A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• N/A
  NCT01779921 · Treatment of Congenital Factor VII Deficiency

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Congenital FVII Deficiency · study director
• Ph3
  NCT01778023 · Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature

  Novo Nordisk A/S · completed · Growth Disorder, Idiopathic Short Stature · study director
• Ph1
  NCT01773798 · A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph1
  NCT01766245 · A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph2
  NCT01751152 · A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

  Novo Nordisk A/S · completed · Inflammation, Crohn's Disease · study director
• Ph4
  NCT01734447 · Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

  Novo Nordisk A/S · completed · Foetal Growth Problem, Small for Gestational Age · study director
• Ph4
  NCT01734486 · Growth Response in Girls With Turner Syndrome

  Novo Nordisk A/S · completed · Genetic Disorder, Turner Syndrome · study director
• Ph3
  NCT01731600 · A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

  Novo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A · study director
• Ph1
  NCT01730014 · A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Healthy · study director
• Ph4
  NCT01720303 · Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01720446 · Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph4
  NCT01720290 · Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01713530 · A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 2 · study director
• Ph3
  NCT01710696 · Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome

  Novo Nordisk A/S · completed · Genetic Disorder, Turner Syndrome · study director
• Ph3
  NCT01709929 · Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
• Ph1
  NCT01707160 · Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers

  Novo Nordisk A/S · completed · Diabetes, Healthy · study director
• Ph3
  NCT01707134 · Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes

  Novo Nordisk A/S · completed · Diabetes, Diabetes Mellitus, Type 1 · study director
• Ph2
  NCT01706159 · A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

  Novo Nordisk A/S · terminated · Inflammation, Ulcerative Colitis · study director
• Ph1
  NCT01706783 · A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

  Novo Nordisk A/S · completed · Growth Hormone Disorder, Adult Growth Hormone Deficiency · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.